Kemin Industries, a global ingredient manufacturer, has acquired HENNESSY RESEARCH ASSOCIATES, LLC (HRA) for an undisclosed amount. This transaction sees Kemin Industries purchasing the animal health research and development firm outright, integrating HRA’s specialized expertise into its operations.
HENNESSY RESEARCH ASSOCIATES, LLC is deeply committed to the research and development of animal health products, vaccines, and diagnostic tests. Led by Dr. Kristina J. Hennessy, who has over 30 years of experience in animal health R&D and holds several patents for infectious disease products, HRA specializes in vaccine development for infectious diseases of animals. Its scientists are skilled in biological manufacturing processes, in vitro test development, lab animal and host animal challenge model development, and USDA ELISA Reference Requalification methods, providing high-quality, safe, and cost-effective solutions to the animal health industry.
The acquisition is a strategic move for Kemin Industries to significantly bolster its capabilities in the animal health sector. By buying HRA, Kemin gains access to advanced research methodologies, intellectual property, and a team of highly qualified scientists dedicated to advancing animal welfare. This integration is expected to create substantial synergies, accelerating the development and delivery of innovative vaccines and diagnostic tools to the global market.
This corporate acquisition underscores Kemin’s commitment to expanding its portfolio of health and nutrition solutions. The combined entity is positioned to enhance its offerings to clients, providing more comprehensive and integrated solutions for animal health challenges worldwide. The outlook for the newly combined operations includes strengthened R&D pipelines and increased capacity for addressing critical needs in veterinary medicine.